Xeris Pharmaceuticals Inc XERS

NAS: XERS | ISIN: US98422L1070   31/05/2024
2,255 USD (+1,58%)
(+1,58%)   31/05/2024

9 november 2023 · Thinking about buying stock in Ventyx Biosciences, Braskem SA, Lithium Americas Corp, Establishment Labs, or Xeris Biopharma Holdings? · Persbericht

13 januari 2022 · PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome · Persbericht

24 juni 2021 · Form 8.3 - Xeris Pharmaceuticals Inc · Persbericht

24 juni 2021 · Form 8.3 -Strongbridge Biopharma plc · Persbericht

22 juni 2021 · Form 8.3 -Strongbridge Biopharma plc · Persbericht

15 juni 2021 · Form 8.3 -Xeris Pharmaceuticals Inc · Persbericht

14 juni 2021 · Form 8.3 -Strongbridge Biopharma plc · Persbericht

9 juni 2021 · Form 8.3 -Xeris Pharmaceuticals Inc · Persbericht

4 juni 2021 · Form 8.3 - Xeris Pharmaceuticals Inc · Persbericht

4 juni 2021 · Form 8.3 -Strongbridge Biopharma plc · Persbericht

3 juni 2021 · Form 8.3 - Xeris Pharmaceuticals Inc · Persbericht

2 juni 2021 · Form 8.3 - Xeris Pharmaceuticals Inc · Persbericht

2 juni 2021 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TLND, XERS, SNX, FI, HGV, STAY; Shareholders are Encouraged to Contact the Firm · Persbericht

31 mei 2021 · Form 8.3 -Xeris Pharmaceuticals Inc · Persbericht

24 mei 2021 · Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases · Persbericht

12 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals, Inc. - XERS · Persbericht

10 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Xeris Pharmaceuticals, Inc. - XERS · Persbericht

Mijn selecties